Media stories about Kite Pharma (NASDAQ:KITE) have trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kite Pharma earned a news impact score of 0.22 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.7341715668319 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Kite Pharma (KITE) remained flat at $$179.79 during mid-day trading on Thursday. The company has a market capitalization of $10,280.00 and a P/E ratio of -26.06. Kite Pharma has a 12-month low of $39.82 and a 12-month high of $179.95.
Kite Pharma Company Profile
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
What are top analysts saying about Kite Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Kite Pharma and related companies.